Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The seven-year update of IRIS (a phase-3 International Randomized Study of Interferon and STI571), which randomized chronic-phase CML (CP-CML) patients to IFNa/AraC or imatinib (400 mg/d), showed an 81% EFS and 86% OS for imantinib.

Strategies for Monitoring Tyrosine Kinase Inhibitor Response in Chronic Phase CML and the Role of Second-Line Inhibitors in Disease Management